APCN 2021: New paradigm in CKD treatment with SGLT2 inhibitors
13 Oct 2021;
Chronic kidney disease (CKD) is a serious and progressive condition, which presents a considerable health burden throughout the world. Early screening and treatment may help improve renal outcomes and reduce the associated risk of mortality. At the Asian Pacific Congress of Nephrology (APCN) 2021, Professor Sydney Tang of the University of Hong Kong and Professor David Wheeler of the University College London, UK, discussed the importance of CKD screening and reviewed treatment options.
Indications/Uses : In combination w/ a SSRI or SNRI for adults w/ treatment-resistant major depressive disorder, who have not responded to at least 2 different treatments w/ antidepressants in the current moderate to severe depressive episode.